18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
about
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasPredictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive LymphomaThe use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapyAssessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary studyDiffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classificationPositron Emission Tomography (PET) in OncologyComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalPredictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysisCirculating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker studyPET/MRI for the evaluation of patients with lymphoma: initial observations.Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis.Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphomaCombination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic MonitoringRole of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma.Impact of FDG-PET/CT in the management of lymphoma.18[F]FDG-PET/CT is a useful molecular marker in evaluating tumour aggressiveness: a revised understanding of an in-vivo FDG-PET imaging that alludes the alteration of cancer biology.Advances in oncologic imaging: update on 5 common cancers.Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma.The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma.PET/CT in malignant lymphoma: basic information, clinical application, and proposal.When should FDG-PET be used in the modern management of lymphoma?Current role of FDG PET/CT in lymphoma.Role of PET in lymphoma.Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection.Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy.PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.Imaging of primary pediatric lymphoma of bone.Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
P2860
Q26752284-227AFA81-FB3A-4A39-A830-861B17291D15Q26771059-3ADA8091-546B-4AE7-B5CB-DE7854DC4FCCQ26863624-7F527603-BB04-4D1A-957B-B2CF62CB5E4FQ33620670-9D0A37EC-16C7-41D5-944D-3EF0CB97EE8FQ33631226-3DD47486-8EEB-4B5E-AC19-7C89B52A640AQ34663865-2C0E7EFE-1EB9-4EBB-B995-B4DE781A3748Q34774840-BE49DD00-0E36-4E2C-AC6A-742796CABD0EQ34918948-84360654-5182-4A07-96C2-CB87755E6F5DQ35091121-90D1B14D-2A86-4E5B-AD6E-2864AF956947Q35700203-67925885-2524-4AF7-B608-E594F519B658Q35737190-327140A9-0C1A-465A-812A-CFE95E30E8C9Q35858346-7A577B1E-B983-412A-8F17-9E0D121968E1Q36344057-BB27BB9E-4FDF-4628-BA09-E9C74564259CQ36417808-8DDC9736-3480-4D87-8ACE-BCAFD4525D85Q36563201-6F903E10-9A6F-4419-AD5D-6951F50F5F6EQ36897012-AD1ECD12-8EEF-466E-962B-75D721216B30Q37069297-E00C78F9-61D5-411A-ADDD-B58998B74A02Q37240835-13268962-6E2B-4AE2-881E-DF69B0ABF92CQ37605897-61D6A6B1-5F65-4DF4-B553-F13EDBD6BF2AQ37702163-71221332-BB3A-4B22-8C18-33459CF28755Q37950857-446350B9-C902-414F-B98E-0DFE865153BBQ38025952-B05ED882-163B-40C5-A4F2-04D8DEA0CC2AQ38052458-0BDE3319-230B-4723-A0BE-599FA14819BFQ38085077-CE8BF3AD-B8B3-4C8E-BE02-56DA11633D05Q38125428-9E38AAD3-9DFC-4DE0-92E7-8527419A1D93Q38142869-8027241D-8AD8-4B9B-9199-8F30E3DB5422Q38153086-5514303C-C3B9-46EA-85A0-1B25CEFB7D84Q38187365-9532A03D-92AF-46B4-ACBB-50E0061DEB9AQ38195220-AB862727-BEED-4C19-A4F8-C6F35E2704E6Q38234470-4FD595BA-84BF-41DA-9F18-7DF39F1B914BQ38400848-55D335AD-449D-4E0D-9A7A-59B3F5F6ABC4Q38552173-9A77AE08-EC9E-4101-A718-EEEA72583ADFQ38622719-3BC10A6A-209F-4C33-97DC-3F1FE1D5AF0CQ38688797-47296FBE-E11D-494A-9D9D-5C4F198F15DBQ38763481-3C51D59C-98EF-4EE0-BE91-AEB62C47F3F8Q38794783-2E40BEA0-402D-44E1-8CA4-F2BBF1D16E69Q38797810-2E33554F-32C4-4BB5-BE7F-F6DD5D9B17E4Q38909384-8792B161-B589-4BC0-8D12-11BB4370E38AQ39324849-A23C26AA-2D8C-42A3-BC4B-2B70DA50F56AQ40356629-A23003A9-AD29-4D24-97BA-059E15E0E742
P2860
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
18F-FDG PET/CT for early respo ...... zation project interpretation.
@ast
18F-FDG PET/CT for early respo ...... zation project interpretation.
@en
type
label
18F-FDG PET/CT for early respo ...... zation project interpretation.
@ast
18F-FDG PET/CT for early respo ...... zation project interpretation.
@en
prefLabel
18F-FDG PET/CT for early respo ...... zation project interpretation.
@ast
18F-FDG PET/CT for early respo ...... zation project interpretation.
@en
P2093
P2860
P1476
18F-FDG PET/CT for early respo ...... zation project interpretation.
@en
P2093
Amanda F Cashen
Andrew Homb
Barry A Siegel
Farrokh Dehdashti
Jingqin Luo
P2860
P304
P356
10.2967/JNUMED.110.082586
P407
P577
2011-02-14T00:00:00Z